补体抑制时代IgA肾病管理的挑战
IgA肾病是最常见的肾小球疾病,年发病率约25/百万成人;部分患者优化支持治疗后仍无法控制病情。KDIGO 2021指南建议此类患者考虑糖皮质激素,但副作用显著。本综述评估补体在IgA肾病病理生理中的作用,并探讨靶向补体抑制剂对未来临床实践的影响。
要点
- IgA肾病年发病率约25/百万成人,部分患者优化支持治疗后仍进展。
- KDIGO 2021指南建议此类患者考虑糖皮质激素,但副作用显著。
- 补体系统在IgA肾病发病中起重要作用,多种补体抑制剂进入后期临床开发。
核心结论
- 补体系统在IgA肾病发病中起重要作用,靶向补体抑制剂可能影响未来临床实践。
- 需评估替代途径和凝集素途径对疾病发病的相对贡献,并确定驱动IgA肾病进展的主要途径。
研究设计与样本
- 综述,评估补体在IgA肾病病理生理中的作用及靶向补体抑制剂对未来临床实践的影响。
主要发现
- IgA肾病是最常见的肾小球疾病,估计年发病率为25/百万成人。
- 尽管优化支持治疗,部分患者仍无法达到疾病控制并出现肾功能进行性恶化。
- KDIGO 2021指南建议对此类患者考虑糖皮质激素,但其使用与显著副作用相关。
- 补体系统在IgA肾病发病中起重要作用已被充分记录,多种补体抑制剂正在进入后期临床开发。
关键数值与推荐
- KDIGO 2021指南建议对优化支持治疗后仍无法控制疾病的IgA肾病患者考虑糖皮质激素。
临床怎么用
- 综述建议需持续研究肾活检补体蛋白染色及识别靶向生物标志物,以评估疾病进展和治疗反应,支持新疗法在临床实践中的实施。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IgA nephropathy (IgAN) is the most common glomerular disease worldwide, with an estimated annual incidence of 25 per million adults. Despite optimized supportive care, some patients fail to achieve disease control and suffer progressive deterioration of kidney function. In this subpopulation of patients, the Kidney Disease: Improving Global Outcomes 2021 guidelines recommend consideration of corticosteroids; however, their use is associated with significant side effects. Ongoing clinical trials are expected to identify corticosteroid-sparing therapies to help improve treatment and prognosis for patients with IgAN. It has been well-documented that the complement system plays a significant role in IgAN pathogenesis, and several complement inhibitors are now entering late-stage clinical development. This review evaluates what we know about the role of complement in the pathophysiology of IgAN and considers how the availability of targeted complement inhibitors may impact future clinical practice. Key knowledge gaps are evaluated, and research opportunities are recommended to help guide clinical decision-making and optimize patient outcomes. Such gaps include evaluating the relative contribution of the alternative and lectin pathways to disease pathogenesis, and the importance of determining the dominant pathway driving IgAN progression. Continued research into the staining of complement proteins in kidney biopsies and identifying targeted biomarkers to assess disease progression and treatment responses will also be needed to support the implementation of newer therapies in clinical practice. Considering the future horizons for enhancing the care of patients with IgAN, tackling the outstanding challenges now will help prepare for the best possible future outcomes.
引用
- Tesař V, Radhakrishnan J, Charu V, et al. Challenges in IgA Nephropathy Management: An Era of Complement Inhibition. Kidney Int Rep. 2023. PMID: 37705895. doi:10.1016/j.ekir.2023.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。